FDA, Parkinson's disease
A new treatment option gets FDA approval for adults with advanced Parkinson’s disease
The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with advanced Parkinson's disease. This novel treatment is the first of its kind,
Injectable drug to ease advanced Parkinson's disease symptoms approved by FDA
The FDA on Thursday approved an injectable drug that eased Parkinson's disease symptoms and improved motor fluctuations in study participants.
FDA Approves New Treatment for Advanced Parkinson’s Disease
The FDA has just approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa).
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system innovation in the space as drugmakers sought to avoid the common pitfall | The 24-hour Parkinson's disease therapy crossed the FDA finish line after an initial manufacturing-related rejection last year and another snub in June.
AbbVie’s Vyalev receives US FDA approval to treat adults living with advanced Parkinson's disease
North Chicago, Illinois Saturday, October 19, 2024, 12:00 Hrs [IST]
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
AbbVie ABBV announced that the FDA has approved its subcutaneous administered drug ABBV-951 to treat motor fluctuations in adult patients with advanced Parkinson's disease (PD). The drug will be marketed under the trade name Vyalev.
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor fluctuations in adults with advanced Parkinson’s disease (PD). The approval was supported by the pivotal 12-week Phase 3 study evaluating the efficacy of continuous subcutaneous infusion of Vyalev in adult patients with advanced PD compared to oral immediate-release carbidopa/levodopa (CD/LD IR),
What to Know About Parkinson’s Disease, According to a Neurologist
Parkinson's disease has been getting increased attention in the media, but misinformation abounds. Here, a Parkinson's expert ...
Man’s simple act of kindness meant the world to woman with Parkinson’s disease
"It's the little things in life that really matter," Liz Marshall told News 4, after nominating the driver of a Waste ...
emjreviews.com11h
24-Hour Therapy for Parkinson’s: The First Of Its Kind
The U.S. FDA has approved the first 24-hour continuous subcutaneous infusion for adults with advanced Parkinson’s disease.
CBS Miami Ted Scouten's personal journey with Parkinson's disease
"We, 100% can tell everyone who comes in the room who is diagnosed with PD, if you exercise, your disease will go slower than ...
Science Daily1d
Parkinson's News
Some Diabetes Drugs Tied to Lower Risk of Dementia, Parkinson's Disease Sep. 18, 2024 — A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease ...
Money Talks News on MSN1d
2 Types of Body Fat Are Now Linked to Dementia, Parkinson’s Risk
Carrying excess fat in your arms and belly might put you at higher risk for Alzheimer’s disease and Parkinson’s disease, ...
BMJ1d
We need to rethink outcomes in Parkinson’s disease research
Over-reliance on symptom scales complicates the interpretation of research results for patients and clinicians. For future ...
Science Daily9d
Parkinson's Research News
Some Diabetes Drugs Tied to Lower Risk of Dementia, Parkinson's Disease Sep. 18, 2024 — A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease ...